The 20th Anniversary of Pharmaceuticals—Heterocyclic Compounds and Their Application in Therapy

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 3395

Special Issue Editors


E-Mail Website
Guest Editor
INSA Rouen Normandie, Univ. Rouen Normandie, CNRS UMR 6014 COBRA, FR 3038, F-76000 Rouen, France
Interests: chemistry of heterocyclic compounds; microwave-assisted chemistry; sustainable methodologies; green chemistry applied to bioactive compounds: kinase inhibitors; Alzheimer's disease; down syndrome; cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Cibles et Médicaments des Infections et de l’immunité, Nantes Université, IICiMed, UR 1155, 44000 Nantes, France
Interests: design, synthesis and biological evaluation of heterocyclic compounds for therapeutic purposes (mycology, parasitology, bacteriology and cancer); inhibitors of kinase signaling pathways; ADMET properties of molecules of biological interest
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heterocycles are present in numerous organic compounds of interest in biology, pharmacology, and medicine. Aromatic and non-aromatic molecules are still some of the largest areas of research in organic and medicinal chemistry. Efforts in exploring novel techniques or methods for synthesizing and functionalizing these compounds have increased, becoming some of the major axes of sustainable chemistry. Heterocycles exhibit unique structures, leading to several applications in the design of drugs. The presence of heteroatoms (e.g., N, S, and O) in the cyclic molecular structures results in significant physicochemical properties. Hydrogen bond donors and acceptors in these rigid frameworks allow hydrogen bond interactions with receptors and/or target enzymes, enhancing binding affinity and improving therapeutic potency. Heterocycles can also be involved in the design of prodrugs and modulate the lipophilicity of bioactive molecules, thus varying their pharmacokinetic and pharmaceutical properties. This Special Issue aims to review recent developments in the design, synthesis, and pharmaceutical properties of natural products as well as synthetic compounds containing aromatic heterocyclic systems. 

Prof. Dr. Thierry Besson
Prof. Dr. Pascal Marchand
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

27 pages, 6049 KiB  
Review
Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development
by Mayara Nascimento, Stefany Moura, Lidia Parra, Valeska Vasconcellos, Gabriela Costa, Debora Leite, Maria Dias, Tácio Vinício Amorim Fernandes, Lucas Hoelz, Luiz Pimentel, Monica Bastos and Nubia Boechat
Pharmaceuticals 2024, 17(10), 1361; https://doi.org/10.3390/ph17101361 - 11 Oct 2024
Cited by 1 | Viewed by 2701
Abstract
The primary treatment for chronic myeloid leukemia (CML) involves first- and second-generation tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, bosutinib, and dasatinib. However, these medications are ineffective against mutations in the kinase domain of the ABL1 protein, particularly in the protein with [...] Read more.
The primary treatment for chronic myeloid leukemia (CML) involves first- and second-generation tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, bosutinib, and dasatinib. However, these medications are ineffective against mutations in the kinase domain of the ABL1 protein, particularly in the protein with the T315I mutation. To address this, ponatinib (PNT), a third-generation inhibitor, was developed. Despite its efficacy in treating the BCR-ABL1T315I mutation, the use of PNT was briefly suspended in 2013 due to serious adverse effects but was subsequently reintroduced to the market. During the drug discovery and development process, it is rare to consolidate all information into a single article, as is the case with ponatinib. This review aims to compile and chronologically organize the research on the discovery of ponatinib using medicinal chemistry tools and computational methods. It includes in silico calculations, such as the octanol/water partition coefficient (cLogP) via SwissAdme, and 2D maps of intermolecular interactions through molecular docking. This approach enhances understanding for both specialists and those interested in medicinal chemistry and pharmacology, while also contextualizing future directions for further optimizations of ponatinib, facilitating the development of new analogs of this crucial inhibitor for the treatment of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Full article
Show Figures

Figure 1

Back to TopTop